Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy

IUBMB Life

Volumn 63, Issue 10, 2011, Pages 806-810

  Triebel, Jakob ^a   MacOtela, Yazmín ^a   De La Escalera, Gonzalo Martínez ^a   Clapp, Carmen ^a  

^a INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

Author keywords

16 kDa prolactin; angiogenesis inhibitors; diabetic complications; diabetic retinopathy; hormones; pregnancy; prolactin; retina; vasoinhibins

Indexed keywords

ACETYLCHOLINE; BRADYKININ; BROMOCRIPTINE; CATHEPSIN D; CYCLIN D2; GLUCOKINASE; GLUCOSE TRANSPORTER 2; GROWTH HORMONE; HYPOPHYSIS HORMONE; INHIBIN; INTERLEUKIN 1BETA; JANUS KINASE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROCOLLAGEN C PROTEINASE; PROLACTIN; PYRUVATE DEHYDROGENASE; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C; STAT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASOINHIBIN;

ACROMEGALY; ANTIANGIOGENIC ACTIVITY; BLINDNESS; BLOOD VESSEL PERMEABILITY; CHOROID; CILIARY BODY; CLINICAL FEATURE; CONFERENCE PAPER; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME ACTIVITY; EYE PROTECTION; GENE DELETION; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSECTOMY; HYPOPHYSIS; HYPOXIA; ISCHEMIA; LASER COAGULATION; NONHUMAN; PATHOPHYSIOLOGY; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY DIABETES MELLITUS; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA; RISK FACTOR; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPERPROLACTINEMIA; PITUITARY GLAND; PREGNANCY; PROLACTIN;

EID: 80053311389     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.518     Document Type: Conference Paper

References (52)

1. Wild, S., Roglic, G., Green, A., Sicree, R., and, King, H., (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053. (Pubitemid 38579764)
2. Klein, R., Klein, B. E., Moss, S. E., Davis, M. D., and, DeMets, D. L., (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 102, 520-526. (Pubitemid 14127838)
3. Gardner, T. W., Abcouwer, S. F., Barber, A. J., and, Jackson, G. R., (2011) An integrated approach to diabetic retinopathy research. Arch. Ophthalmol. 129, 230-235.
4. Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., et al. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40-51.
5. Vasilaki, A., and, Thermos, K., (2009) Somatostatin analogues as therapeutics in retinal disease. Pharmacol. Ther. 122, 324-333.
6. The Diabetes Control and Complications Trial Research Group (2000) Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 23, 1084-1091.
7. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
8. Brownlee, M., (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820. (Pubitemid 34000785)
9. Cheung, N., Mitchell, P., and, Wong, T. Y., (2010) Diabetic retinopathy. Lancet 376, 124-136.
10. Hammes, H. P., Feng, Y., Pfister, F., and, Brownlee, M., (2008) Diabetic retinopathy: targeting vasoregression. Diabetes 60, 9-16.
11. Wirostko, B., Wong, T. Y., and, Simo, R., (2008) Vascular endothelial growth factor and diabetic complications. Prog. Retin. Eye Res. 27, 608-621.
12. Simo, R., and, Hernandez, C., (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51, 1574-1580.
13. Clapp, C., Thebault, S., Jeziorski, M. C., and, Martinez De La Escalera, G., (2009) Peptide hormone regulation of angiogenesis. Physiol. Rev. 89, 1177-1215.
14. Poulsen, J. E., (1953) Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 2, 7-12.
15. No authors listed (1968) Pituitary ablation for diabetic retinopathy. Br. Med. J. 2, 254-255.
16. Saglam, S., Wilson, C. B., and, Seymour, R. J., (1970) Indications for hypophysectomy in diabetic retinopathy and cancer of the breast and prostate. Calif. Med. 113, 1-6.
17. Frystyk, J., (2005) The growth hormone hypothesis-2005 revision. Horm. Metab. Res. 37 (Suppl 1), 44-48.
18. Powell, E. D., Frantz, A. G., Rabkin, M. T., and, Field, R. A., (1966) Growth hormone in relation to diabetic retinopathy. N. Engl. J. Med. 275, 922-925.
19. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001) The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108, 2266-2272.
20. Wang, Q., Dills, D. G., Klein, R., Klein, B. E., and, Moss, S. E., (1995) Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 44, 161-164.
21. Ballintine, E. J., Foxman, S., Gorden, P., and, Roth, J., (1981) Rarity of diabetic retinopathy in patients with acromegaly. Arch. Intern. Med. 141, 1625-1627. (Pubitemid 12234069)
22. Laron, Z., and, Weinberger, D., (2004) Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur. J. Endocrinol. 151, 103-106. (Pubitemid 39117370)
23. Freeman, M. E., Kanyicska, B., Lerant, A., and, Nagy, G., (2000) Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523-1631.
24. Laway, B., Bashir, M., Ganie, M., Mir, S., Gojwari, T., et al. (2010) Hyperprolactinemia in a patient with Sheehan's syndrome. Turk. JEM 14, 47-49.
25. Brelje, T. C., Scharp, D. W., Lacy, P. E., Ogren, L., Talamantes, F., et al. (1993) Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology 132, 879-887. (Pubitemid 23056153)
26. Friedrichsen, B. N., Richter, H. E., Hansen, J. A., Rhodes, C. J., Nielsen, J. H., et al. (2003) Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. Mol. Endocrinol. 17, 945-958. (Pubitemid 36539583)
27. Petryk, A., Fleenor, D., Driscoll, P., and, Freemark, M., (2000) Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2. J. Endocrinol. 164, 277-286. (Pubitemid 30163670)
28. Weinhaus, A. J., Stout, L. E., Bhagroo, N. V., Brelje, T. C., and, Sorenson, R. L., (2007) Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J. Endocrinol. 193, 367-381. (Pubitemid 47028688)
29. Arumugam, R., Horowitz, E., Noland, R. C., Lu, D., Fleenor, D., and, Freemark, M., (2010) Regulation of islet beta-cell pyruvate metabolism: interactions of prolactin, glucose, and dexamethasone. Endocrinology 151, 3074-3083.
30. Kim, H., Toyofuku, Y., Lynn, F. C., Chak, E., Uchida, T., et al. (2010) Serotonin regulates pancreatic beta cell mass during pregnancy. Nat. Med. 16, 804-808.
31. Huang, C,., Snider, F,., Cross, J. C., (2009) Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. Endocrinology 150, 1618-1626.
32. Freemark, M., Avril, I., Fleenor, D., Driscoll, P., Petro, A., Opara, E., et al. (2002) Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 143, 1378-1385. (Pubitemid 34274368)
33. Holstad, M., and, Sandler, S., (1999) Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice. J. Endocrinol. 163, 229-234.
34. Cruz-Soto, M. E., Cosio, G., Jeziorski, M. C., Vargas-Barroso, V., Aguilar, M. B., et al. (2009) Cathepsin D is the primary protease for the generation of adenohypophyseal vasoinhibins: cleavage occurs within the prolactin secretory granules. Endocrinology 150, 5446-5454.
35. Macotela, Y., Aguilar, M. B., Guzman-Morales, J., Rivera, J. C., Zermeno, C., et al. (2006) Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J. Cell Sci. 119, 1790-1800. (Pubitemid 43811005)
36. Duenas, Z., Torner, L., Corbacho, A. M., Ochoa, A., Gutierrez-Ospina, G., et al. (1999) Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest. Ophthalmol. Vis. Sci. 40, 2498-2505. (Pubitemid 29455476)
37. Pan, H., Nguyen, N. Q., Yoshida, H., Bentzien, F., Shaw, L. C., et al. (2004) Molecular targeting of antiangiogenic factor 16 K hPRL inhibits oxygen-induced retinopathy in mice. Invest. Ophthalmol. Vis. Sci. 45, 2413-2419. (Pubitemid 38902617)
38. Garcia, C,., Aranda, J,., Arnold, E,., Thebault, S,., Macotela, Y,., et al. (2008) Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J. Clin. Invest. 118, 2291-2300. (Pubitemid 351872346)
39. Aranda, J,., Rivera, J. C,., Jeziorski, M. C,., Riesgo-Escovar, J,., Nava, G,., et al. (2005) Prolactins are natural inhibitors of angiogenesis in the retina. Invest. Ophthalmol. Vis. Sci. 46, 2947-2953. (Pubitemid 43086718)
40. Rivera, J. C., Aranda, J., Riesgo, J., Nava, G., Thebault, S., et al. (2008) Expression and cellular localization of prolactin and the prolactin receptor in mammalian retina. Exp. Eye Res. 86, 314-321.
41. O'steen, W. K., and, Sundberg, D. K., (1982) Patterns of radioactivity in the eyes of rats after injection of iodinated prolactin. Ophthalmic Res. 14, 54-62. (Pubitemid 12183797)
42. Arnold, E., Rivera, J. C., Thebault, S., Moreno-Paramo, D., Quiroz-Mercado, H., et al. (2010) High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes 59, 3192-3197.
43. Mestriner, A. C., and, Haddad, A., (1997) Horseradish peroxidase: a reliable or a misleading tool for the investigations on the origin of the proteins of the aqueous humor? Cell Tissue Res. 289, 85-96. (Pubitemid 27279874)
44. Duenas, Z., Rivera, J. C., Quiroz-Mercado, H., Aranda, J., Macotela, Y., et al. (2004) Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest. Ophthalmol. Vis. Sci. 45, 2049-2055. (Pubitemid 38902570)
45. Mooradian, A. D., Morley, J. E., Billington, C. J., Slag, M. F., Elson, M. K., and, Shafer, R. B., (1985) Hyperprolactinaemia in male diabetics. Postgrad. Med. J. 61, 11-14.
46. Harter, M., Balarac, N., Pourcher, P., Koslowski, J. M., Krebs, B., and, Ramaioli, A., (1976) Diabetic retinopathy and prolactin. Lancet 2, 961-962.
47. Triebel, J., Huefner, M., and, Ramadori, G., (2009) Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy. Eur. J. Endocrinol. 161, 345-353.
48. Lawrence, R. D., (1948) Acute retinopathy without hyperpiesis in diabetic pregnancy. Br. J. Ophthalmol. 32, 461-465.
49. Ringholm, L., Vestgaard, M., Laugesen, C. S., Juul, A., Damm, P., and, Mathiesen, E. R., (2011) Pregnancy-induced increase in circulating IGF-I is associated with progression of diabetic retinopathy in women with type 1 diabetes. Growth Horm. IGF Res. 21, 25-30.
50. Ben-Jonathan, N., LaPensee, C. R., and, LaPensee, E. W., (2008) What can we learn from rodents about prolactin in humans? Endocr. Rev. 29, 1-41. (Pubitemid 351252745)
51. Larinkari, J., Laatikainen, L., Ranta, T., Moronen, P., Pesonen, K., and, Laatikainen, T., (1982) Metabolic control and serum hormone levels in relation to retinopathy in diabetic pregnancy. Diabetologia 22, 327-332. (Pubitemid 12154517)
52. Zhang, L., Krzentowski, G., Albert, A., and, Lefebvre, P. J., (2001) Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24, 1275-1279. (Pubitemid 33716411)